Mounjaro 'discount codes' on TikTok: what's actually going on?

What did @sixty.clicks.club actually say?

Not much, medically speaking. The transcript contains exactly one line: "It's me, I'm the director I'm the director I'm the director." That's it. The actual substance of this post lives in the caption, which advertises "June prices" for what appears to be Mounjaro (tirzepatide), promotes a "half price" deal, and asks viewers to DM for discount codes. The video itself makes no clinical claims whatsoever.

That gap between a content-free video and a caption pushing pharmaceutical discount codes is worth sitting with. The creator is essentially using a personality hook to drive people into a private DM channel where pricing information for a controlled medication gets exchanged. That's a sales funnel, not health education.

Does the science back this up?

There's nothing to evaluate scientifically here because no scientific claim was made. Tirzepatide, the active ingredient in Mounjaro and Zepbound, does have strong clinical evidence behind it. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5% mean body weight reduction at the highest dose in adults with obesity. That evidence is real and impressive.

But none of that is what this video is about. This video is about pricing and discount codes for a GLP-1 medication. The question worth asking is: what product is actually being sold at "half price"? Brand-name Mounjaro from a licensed pharmacy does not get sold at half price through TikTok DMs. Compounded tirzepatide from a 503A or 503B pharmacy is a different product entirely, and the FDA has made clear that compounded versions are not therapeutically equivalent to FDA-approved drugs.

What did they get wrong (or right)?

The creator didn't get anything clinically wrong because they didn't say anything clinical. What they did do is run a promotional campaign for discounted GLP-1 medication through an unverifiable private channel, and that raises several legitimate concerns.

• "Half price" GLP-1 medications promoted via social media DMs are almost always compounded tirzepatide or semaglutide, not brand-name Mounjaro or Wegovy. Compounded drugs are not FDA-approved and have no requirement to demonstrate bioequivalence.
• The FDA issued a warning in 2024 specifically about compounded semaglutide and tirzepatide, noting reports of adverse events including hospitalizations linked to dosing errors and product quality issues.
• Soliciting DMs for medication pricing on a platform with no age verification, no prescriber involvement, and no pharmacy licensing disclosure is a pattern regulators have flagged repeatedly.

To be fair: there is nothing in the video itself that is false. But the framing, the hashtags, and the CTA together paint a picture that deserves scrutiny.

What should you actually know?

If you're on a GLP-1 like tirzepatide and cost is a real barrier, there are legitimate pathways. Eli Lilly's Savings Card program has offered Mounjaro for as low as $25/month for eligible commercially insured patients. For uninsured patients, patient assistance programs exist through the manufacturer directly.

Compounded tirzepatide became widely available during the FDA shortage period, and some telehealth platforms do offer it legally through licensed 503A compounding pharmacies with a valid prescription. But the keyword is licensed, and the prescription has to come from a provider who has actually evaluated you, not from a DM conversation initiated by a TikTok discount code.

The FDA removed tirzepatide from its drug shortage list in late 2024, which means compounding pharmacies may no longer be legally permitted to compound it for general dispensing under the same shortage exemptions. Anyone being offered "half price Mounjaro" right now should ask very specific questions about what product they are actually receiving, from which pharmacy, under which license, and prescribed by whom.